Incyte

Incyte

A global biopharmaceutical company focused on the discovery and development of small-molecule drugs.

Incyte is a global biopharmaceutical company, founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. The company has grown to employ over 1400 people and has operations in the U.S., Europe, and Japan. Incyte focuses on the discovery and development of small-molecule drugs.

The company has a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. They are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.

Covid-19 Treatment

Clinical trials are testing the viability of Incyte drugs for the treatment of coronavirus. As of February 2020, Camrelizumab (humanized monoclonal antibody targeting PD-1) and thymosin are being used in two ongoing clinical trials.

Timeline

People

Name
Role
LinkedIn

Barry P. Flannelly

Executive Vice President, General Manager, US

Christiana Stamoulis

Executive Vice President and Chief Financial Officer

Dashyant Dhanak

Executive Vice President and Chief Scientific Officer

Herve Hoppenot

Chairman, President and Chief Executive Officer

Jonathan E. Dickinson

Executive Vice President and General Manager, Europe

Lothar H. Finke

Head of Clinical Development and General Manager, Japan

Maria E. Pasquale

Executive Vice President, General Counsel

Michael Morrissey

Executive Vice President and Head of Global Technical Operations

Paula J. Swain

Executive Vice President, Human Resources

Steven H. Stein

Executive Vice President, Chief Medical Officer

Vijay Iyengar

Executive Vice President, Global Strategy and Corporate Development

Wenqing Yao

Executive Vice President, Discovery Chemistry

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Eli Lilly and Company; Incyte
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the...
Nick Paul
January 22, 2021
FierceBiotech
The FDA has accepted Incyte's PD-1 inhibitor retifanlimab for priority review in patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC).
Eli Lilly and Company
December 11, 2020
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published...
Innovent Biologics
December 8, 2020
www.prnewswire.com:443
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
December 4, 2020
BioSpace
Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease - read this article along with other careers information, tips and advice on BioSpace
Eli Lilly and Company
November 19, 2020
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an...
BioSpace
November 11, 2020
BioSpace
Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), first-line DLBCL, and relapsed or refractory follicular lymphoma (FL).
Reuters Editorial
April 3, 2020
IN
Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.